Search | IOVS | ARVO Journals

View

Showing 1 – 7 of 7

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract July 2019

EXN407, a novel topical therapeutic candidate with high retinal bioavailability for the treatment of diabetic macular oedema, inhibits ocular neovascularisation

Jennifer Batson; Hamish Toop; Susan Liddell; James Daubney; Elizabeth Anne Stewart; Anthony Habgood; Amy Murphy; Ken McKechnie; Jonathan Morris; David O Bates

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):26. doi:

ARVO Annual Meeting Abstract July 2019

Designing topical VEGF-A inhibitors with high retinal bioavailability using ex vivo permeability modelling

David O Bates; Susan Liddell; Hamish Toop; Elizabeth Anne Stewart; Amy Murphy; Anthony Habgood; James Daubney; Cristina Gutierrez-Caballero; Ken McKechnie; Jonathan Morris; Jennifer Batson

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):3246. doi:

ARVO Annual Meeting Abstract July 2018

A novel approach to inhibit pro-angiogenic VEGF splicing in retinal vascular diseases with topical administration of small molecules optimised for retinal pharmacokinetics

Jennifer Batson; Hamish Toop; Susan Liddell; James Daubney; Elizabeth Stewart; Ken McKechnie; Jonathan Morris; David Bates

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):220. doi:

ARVO Annual Meeting Abstract June 2017

Optimisation of potent SRPK1 inhibitors through modelling of permeability properties required for trans-scleral eye drop delivery

Jennifer Batson; Hamish Toop; Elizabeth Stewart; James Daubney; Jonathan Morris; David O Bates

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1966. doi:

ARVO Annual Meeting Abstract June 2017

Targeting SRPK1 with novel potent and selective small molecule inhibitors inhibits choroidal neovascularisation through modulating VEGF-A alternative splicing

David O Bates; Hamish Toop; James Daubney; Elizabeth Stewart; Jonathan Morris; Jennifer Batson

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):424. doi:

ARVO Annual Meeting Abstract September 2016

Development of topically administered retinal angiogenesis inhibitors with improved ocular permeability and therapeutic exposure in rabbit eyes

Jennifer Batson; Hamish Toop; Jonathan Rowlinson; Claire Louise Allen; Gibbons Brian; Jonathan Morris; David O Bates

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):774. doi:

ARVO Annual Meeting Abstract June 2015

Development of SRPK1 inhibitors as novel anti-angiogenic therapeutics for exudative age-related macular degeneration (AMD)

Jennifer Batson; Hamish Troop; Jonathan Rowlinson; Claire Allen; Roya Babaei-Jadidi; Jingxue Zhang; Stephen Wearmouth; Stefan Knapp; Jonathan Morris; David Bates

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):2461. doi:

Advertisement